Navigation Links
Alseres Pharmaceuticals Expands Sites for the First Stage of the ALTROPANE(R) Phase III Clinical Trial Program
Date:4/17/2008

egenerative therapies including bone repair. The Company has a robust molecular imaging development program targeting diagnosis of Parkinson's disease and potentially dementia and ADHD. The Company's lead molecular imaging product candidate is ALTROPANE which is in Phase III clinical trials for the diagnosis of Parkinsonian Syndromes including Parkinson's Disease. The Company has research collaborations with Harvard Medical School and Children's Hospital Boston.

Forward-Looking Statements

The foregoing release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward- looking statements include statements regarding Alseres Pharmaceuticals' future expectations, beliefs, intentions, goals, strategies, plans or prospects regarding the future, including the development and commercialization of ALTROPANE and CETHRIN, the prospects of the Company's CNS and regenerative therapeutics program, the Company's strategies to develop and commercialize axon regeneration technologies and the breadth of the Company's technologies and intellectual property portfolio. Forward-looking statements can be identified by terminology such as "anticipate," "believe," "could," "could increase the likelihood," "estimate," "expect," "intend," "is planned," "may," "should," "will," "will enable," "would be expected," "look forward," "may provide," "would" or similar terms, variations of such terms or the negative of those terms. Such forward-looking statements involve known and unknown risks, uncertainties and other factors including those risks, uncertainties and factors referred to in the Company's Annual Report on Form 10-K for the year ended December 31, 2007 filed with the Securities and Exchange Commission under the section "Risk Factors," as well as other documents that may be filed by Alseres Pharmaceuticals from time to time with the Securities and Exchange Commission. As a result of such risks, uncertain
'/>"/>

SOURCE Alseres Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Alseres Pharmaceuticals Announces Expansion of the Cethrin(R) Acute Spinal Cord Injury (SCI) Phase I/IIA Clinical Trial
2. Alseres Pharmaceuticals Initiates the ALTROPANE(R) POET-2 Phase III Clinical Trial Program
3. Alseres Pharmaceuticals Concludes Enrollment in the Cethrin(R) Phase I/IIa Clinical Trial in Acute Spinal Cord Injury
4. Alseres Pharmaceuticals, Inc. to Address a Congressional Briefing on Paralysis Research and the Spinal Cord Injury Community at Working 2 Walk in Washington, DC, April 13-15, 2008
5. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
8. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
9. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
10. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
11. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... 23, 2014 According to ... Product (Radiofrequency, Ultrasound, Irreversible Electroporation, Cryotherapy, Microwave), Application ... - Global Forecasts to 2019", published by MarketsandMarkets, studies ... period of 2014 to 2019. The market is ... CAGR of 9.6% from 2014 to 2019. ...
(Date:9/23/2014)... , Sept. 23, 2014 A case report ... a SynCardia temporary Total Artificial Heart into a patient ... ventricles were reversed, along with other abnormalities. ... modifying the SynCardia Total Artificial Heart to treat a ... report and video in the Journal of Visualized Experiments ...
(Date:9/23/2014)... Calif. , Sept. 23, 2014  Savant ... today confirmed the initiation of human safety testing ... of addiction. A single dose of 18-MC, administered ... study conducted by Savant,s South American partner, was ... drug. Savant HWP plans to develop 18-MC as ...
Breaking Medicine Technology:Ablation Technologies Market Worth $3.81 Billion by 2019 2Ablation Technologies Market Worth $3.81 Billion by 2019 3Ablation Technologies Market Worth $3.81 Billion by 2019 41st Use of the SynCardia Total Artificial Heart in a 17-Year-Old Congenital Heart Disease Patient at Pediatric Hospital 21st Use of the SynCardia Total Artificial Heart in a 17-Year-Old Congenital Heart Disease Patient at Pediatric Hospital 31st Use of the SynCardia Total Artificial Heart in a 17-Year-Old Congenital Heart Disease Patient at Pediatric Hospital 4Savant HWP Confirms Initiation of a Human Safety Trial for 18-MC, a Potential Anti-Addiction Therapy 2Savant HWP Confirms Initiation of a Human Safety Trial for 18-MC, a Potential Anti-Addiction Therapy 3
... March 15, 2011 Omeros Corporation (Nasdaq: ... and commercializing products focused on inflammation, bleeding and disorders ... for the fourth quarter and year ended December 31, ... for the three months ended December 31, 2010 were ...
... Pharmacy Benefit Consulting, the nation,s leading Pharmacy Benefit ... their clients. On February 16th, ARMSRx ... Lumber.  It was recommended and modeled by ARMSRx last ... making some simple changes.  The results speak for themselves. ...
Cached Medicine Technology:Omeros Corporation Reports Fourth Quarter and Year-End 2010 Financial Results 2Omeros Corporation Reports Fourth Quarter and Year-End 2010 Financial Results 3Omeros Corporation Reports Fourth Quarter and Year-End 2010 Financial Results 4Omeros Corporation Reports Fourth Quarter and Year-End 2010 Financial Results 5Omeros Corporation Reports Fourth Quarter and Year-End 2010 Financial Results 6ARMSRx and 84 Lumber Hammer Down Rx Costs...Again 2
(Date:9/23/2014)... Mich. They are common suggestions to remedy stress: You ... Get out and see people. , Turns out ... better a lot better a new large scale ... lower depression, less perceived stress and enhanced mental health and ... Michigan, with partners from De Montfort University, James Hutton Institute, ...
(Date:9/23/2014)... ANGELES (September 23, 2014) Laparoscopic cholecystectomy, a minimally ... the most common abdominal surgeries in the U.S. Yet ... to the procedure with some moving patients quickly into ... online Monday in the American Journal of Surgery ... regular working hours rather than rushing the patients into ...
(Date:9/23/2014)... living things function comes from knowledge of structuresatomic details ... receptors that are docking stations for viruses and messenger ... carry genetic blueprints for building cellular machinery, to name ... structural details, a new grant just awarded by the ... of Energy (DOE) will fund the operation of a ...
(Date:9/23/2014)... ADOMANI, Inc. has announced that industry expert ... is a 13-year veteran in the school, commercial and transit ... Bus Sales of Colton, California. While with A-Z Mr. Reynolds ... line revenues, profit and market penetration by double digits. , ... all-electric or plug-in hybrid vehicle conversions. They have converted ...
(Date:9/23/2014)... the European Journal of Cancer presents detailed ... the 1st EORTC Cancer Survivorship Summit held this past ... and more personalized multimodal treatments has boosted survival rates ... and rapidly increasing number of cancer survivors. Despite this ... broad spectrum of late adverse treatment effects and some ...
Breaking Medicine News(10 mins):Health News:Beating stress outdoors? Nature group walks may improve mental health 2Health News:Study finds gallbladder surgery can wait 2Health News:New NIH/DOE grant for life science studies at NSLS-II 2Health News:New NIH/DOE grant for life science studies at NSLS-II 3Health News:ADOMANI Announces Jim Reynolds to Take Over as President and CEO 2
... disease are there, researchers say , WEDNESDAY, Oct. 24 (HealthDay ... show early signs of heart disease -- similar to that ... by a team at Washington University School of Medicine, St. ... the children had undergone cardiac ultrasound to check on symptoms ...
... break-through new way of ... taking daily dose of glucosamine, SAN FRANCISCO, Oct. 24 ... wants to help,people keep their joints hydrated and moving smoothly.* The ... Joint Juice products: -- Original Joint Juice: ready-to-drink juice-based dietary ...
... ), the,global leader in the development, manufacture and supply ... today that it,will broadcast a third quarter 2007 earnings ... 2007 at 10:00 a.m. EDT. The call will,last approximately ... the opportunity to listen to,the conference call live at ...
... FRANCISCO While some targeted therapies drugs ... pathways occurring within cancer cells work well by ... when teamed with other targeted and conventional therapies. ... Molecular Targets and Cancer Therapeutics, multiple-target applications of new ...
... Out of Pocket Expenses ... for Medical Foods, ... BMRN) announced today that it has,provided a $250,000 grant to the ... program for patients with,phenylketonuria (PKU), a rare genetic metabolic disorder. Funds ...
... 24 NutraCea (OTC Bulletin,Board: NTRZ), a health ... bran (SRB) nutrient research and technology whose products ... benefits for,humans and animals announced today that it ... relations services and an expanded,communications program among the ...
Cached Medicine News:Health News:Obesity Can Hurt Kids' Hearts 2Health News:Joint Juice Helps America Hydrate Its Joints* With New High Value Coupon Offer 2Health News:Joint Juice Helps America Hydrate Its Joints* With New High Value Coupon Offer 3Health News:MSA Schedules Third Quarter Earnings Webcast 2Health News:Combination targets: some drugs may work best when they work together 2Health News:Combination targets: some drugs may work best when they work together 3Health News:Combination targets: some drugs may work best when they work together 4Health News:Combination targets: some drugs may work best when they work together 5Health News:Combination targets: some drugs may work best when they work together 6Health News:Combination targets: some drugs may work best when they work together 7Health News:BioMarin Provides Grant to NORD to Expand PKU Patient Support Services 2Health News:BioMarin Provides Grant to NORD to Expand PKU Patient Support Services 3Health News:BioMarin Provides Grant to NORD to Expand PKU Patient Support Services 4Health News:BioMarin Provides Grant to NORD to Expand PKU Patient Support Services 5Health News:NutraCea Appoints Financial Relations Board as New Investor Relations Firm 2Health News:NutraCea Appoints Financial Relations Board as New Investor Relations Firm 3
... automated semen analysis, with accurate, consistent, reliable ... Automation provides standardization and ease of use ... analysis. SPERMALITE is a new-generation automated semen ... analysis, and a hard -copy analysis report ...
Stainless Steel. Sterile. 2 pieces/box...
... Cannulated Screw System is part ... systems developed by DePuy ACE ... 3.5mm to 8.0mm. Complete with ... system was designed with the ...
... The first FDA-cleared third-generation allergy test , ... blood testing. It provides quantitative determination of ... excellent precision, accuracy and lot-to-lot reproducibility. The ... hour to help you identify, monitor and ...
Medicine Products: